Luminex Corporation Announces Pricing of Public Offering of Common Stock
June 25 2008 - 8:00AM
Business Wire
Luminex Corporation (NASDAQ:LMNX) announced today the pricing of
its underwritten public offering of 3,500,000 shares of its common
stock. The Company has granted the underwriters a 30-day option to
purchase up to an additional 525,000 shares of common stock to
cover over-allotments, if any. The offering is expected to close on
June 30, 2008. The offering price to public is $19.91 per share.
Luminex estimates that the net proceeds from the offering will be
approximately $64.5 million, after deducting estimated expenses and
underwriting discounts and commissions. Luminex intends to use the
net proceeds from the offering for general corporate purposes,
including research and development, potential acquisitions and
capital expenditures. J.P. Morgan Securities Inc. and UBS
Investment Bank are acting as joint book-running managers for the
offering. Avondale Partners, LLC, Canaccord Adams Inc. and Leerink
Swann LLC are acting as co-managers for the offering. An
automatically effective shelf registration statement has been filed
with the Securities and Exchange Commission which covers these
securities. The offering is being made solely by means of a
prospectus and prospectus supplement. Copies of the prospectus and
related prospectus supplement may be obtained by mail from:
JPMorgan, National Statement Processing, Prospectus Library, 4
Chase Metrotech Center, CS Level, Brooklyn, NY 11245, telephone:
718-242-8002 or UBS Securities LLC, 299 Park Avenue, New York, NY
10171 Attn: Prospectus Department, or by telephone toll free at
888-827-7275, extension 3884. An electronic copy of the prospectus
and related preliminary prospectus supplement are available on the
website of the Securities and Exchange Commission at
http://www.sec.gov. This press release does not constitute an offer
to sell or the solicitation of an offer to buy the shares of common
stock or any other securities, nor will there be any sale of the
shares of common stock or any other securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any state or jurisdiction. About Luminex
Corporation Luminex develops, manufactures and markets proprietary
biological testing technologies with applications throughout the
life sciences industry. The Company�s xMAP� system is an
open-architecture, multi-analyte technology platform that delivers
fast, accurate and cost-effective bioassay results to markets as
diverse as pharmaceutical drug discovery, clinical diagnostics and
biomedical research, including the genomics and proteomics research
markets. The Company�s xMAP� technology is sold worldwide and is in
use in leading research laboratories as well as major
pharmaceutical, diagnostic and biotechnology companies. Further
information on Luminex or xMAP� can be obtained on the Internet at
http://www.luminexcorp.com. Statements contained in this press
release that are not historical facts are "forward-looking"
statements within the meaning of the federal securities laws.
Forward-looking statements, including statements regarding the
completion of the public offering and any of the terms thereof, are
uncertain and subject to a variety of risks that could cause actual
results to differ materially from those expected by the Company.
Additional information regarding these and other risks effecting
the Company are contained in the Company's registration statement
and the prospectus supplement relating to the offering.
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Luminex (NASDAQ:LMNX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Luminex Corporation (NASDAQ): 0 recent articles
More Luminex Corporation News Articles